A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Saved in:
| Title: | A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. |
|---|---|
| Authors: | Davis SL; University of Colorado Cancer Center, Aurora, Colorado, USA sarah.davis@ucdenver.edu., Eckhardt SG; The University of Texas at Austin Dell Medical School, Austin, Texas, USA., Diamond JR; University of Colorado Cancer Center, Aurora, Colorado, USA., Messersmith WA; University of Colorado Cancer Center, Aurora, Colorado, USA., Dasari A; MD Anderson Cancer Center, Houston, Texas, USA., Weekes CD; Massachusetts General Hospital, Boston, Massachusetts, USA., Lieu CH; University of Colorado Cancer Center, Aurora, Colorado, USA., Kane M; University of Colorado Cancer Center, Aurora, Colorado, USA., Choon Tan A; University of Colorado Cancer Center, Aurora, Colorado, USA., Pitts TM; University of Colorado Cancer Center, Aurora, Colorado, USA., Leong S; University of Colorado Cancer Center, Aurora, Colorado, USA. |
| Source: | The oncologist [Oncologist] 2018 Dec; Vol. 23 (12), pp. 1409-e140. Date of Electronic Publication: 2018 Aug 23. |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 30139840 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Davis+SL%22">Davis SL</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA sarah.davis@ucdenver.edu.<br /><searchLink fieldCode="AU" term="%22Eckhardt+SG%22">Eckhardt SG</searchLink>; The University of Texas at Austin Dell Medical School, Austin, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Diamond+JR%22">Diamond JR</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Messersmith+WA%22">Messersmith WA</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Dasari+A%22">Dasari A</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Weekes+CD%22">Weekes CD</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Lieu+CH%22">Lieu CH</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Kane+M%22">Kane M</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Choon+Tan+A%22">Choon Tan A</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Pitts+TM%22">Pitts TM</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Leong+S%22">Leong S</searchLink>; University of Colorado Cancer Center, Aurora, Colorado, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2018 Dec; Vol. 23 (12), pp. 1409-e140. <i>Date of Electronic Publication: </i>2018 Aug 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30139840 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1634/theoncologist.2018-0315 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1409 Titles: – TitleFull: A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Davis SL – PersonEntity: Name: NameFull: Eckhardt SG – PersonEntity: Name: NameFull: Diamond JR – PersonEntity: Name: NameFull: Messersmith WA – PersonEntity: Name: NameFull: Dasari A – PersonEntity: Name: NameFull: Weekes CD – PersonEntity: Name: NameFull: Lieu CH – PersonEntity: Name: NameFull: Kane M – PersonEntity: Name: NameFull: Choon Tan A – PersonEntity: Name: NameFull: Pitts TM – PersonEntity: Name: NameFull: Leong S IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2018 Dec Type: published Y: 2018 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 23 – Type: issue Value: 12 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |
